TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Inflammatory cytokines levels in ileal mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Willingness to participate in a clinical trial
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: median craving intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Cranio Facial Pain and Disability Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of plasmatic volume estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Numerical Rating Scale (NRS) at PACU arrival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fracture Union
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Fracture Non-union
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Retinal endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the incidence of vasovagal complications
Endpoint domain: Adverse events/effects
Primary endpoint: Chronic HBV clearance and persistence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Respiratory Sinus Arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Any postoperative complication
Endpoint domain: Adverse events/effects
Primary endpoint: Absence of psychological morbidities
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of Modified Preoperative Endocrine Prognostic Index (mPEPI) Score of 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: percent of subjects enrolled to study completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: percent of subjects randomized but did not complete the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: time to accrual of 20 patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: AUC(0-24)md based on nominal dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Drug-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients That do Not Progress
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline of perioperative haemodynamic measurements (HR, MAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery scores (Aldrete, White, Chung)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet Reactivity Units (PRU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uncontrolled major or life-threatening bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urgent surgery or invasive procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Depression Status - Beck Depression Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Depression Status - Diagnosis of Major Depressive Disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Blood pressure during the hemodialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Respiratory rate during the hemodialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: O2 saturation during the hemodialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Comprehensive Knee Osteoarthritis Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hemoglobin variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rectus Femoris Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rectus Femoris Cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: foot placement accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in standardized Gross Motor Function Measure evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved cognitive function as measured by the mini mental state exam
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduced depressive symptoms measured by the Beck Depression Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Absolute change in body mass index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Hair Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Collection and recording of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline to Peak in CSF S100 Beta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline to Peak in CSF Glial Fibrillary Acidic Protein (GFAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety and tolerability of GW786034
Endpoint domain: Adverse events/effects
Primary endpoint: changes in physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Final birthweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Investigator's Rating of Global Photographs
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: decreased narcotic consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Meeting Feasibility Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with no signs of urinary tract infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Pain Severity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Proportion of volunteers with ovulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Biochemical markers of PA variant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in clinician-rated severity of social anxiety or panic disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-reported symptom severity of social anxiety or panic disorder
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Toxicity Based Upon Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Response Evaluation Criteria In Solid Tumors (RECIST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Short term readmission rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of episodes of recurrent chorioretinitis by toxoplasmosis
Endpoint domain: Adverse events/effects
Primary endpoint: Skin melanin index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of infants requiring/starting methadone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infection eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Palatal lengthening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of maternal glycosylated Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Change in Time of Circulating Estradiol SPE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma high-sensitivity cardiac troponin T at day 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in plasma concentration/elimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of aspirated fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: PCR corrected cure rates
Endpoint domain: Mortality/survival
Primary endpoint: Change in the ratio of Residual Volume to Total Lung Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Composite Endpoint of Stroke, SEE, MI and CV Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Composite Endpoints of Major and Clinically-relevant Non-major (CRNM) Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of P2Y12 receptor inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Aberrant Behavior Checklist-Irritability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: early local tumour response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Foot and lower limb kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint moments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Force-time impulses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from recurrent atrial fibrillation and atrial flutter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean difference in Pregnancy-Unique Quantification of Emesis (PUQE) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax - Time of Occurrence of Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t - Area Under the Plasma Concentration Versus Time Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: efficacy readouts after 6 weeks treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epistaxis duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic pain measured by VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: paO2 / FiO2 ratio (Horowitz Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Appetite stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in average threshold of tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Necrosis of the target tumour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Triglycerides Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: High Density Lipoprotein (c-HDL) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Foot Health Status Questionnaire pain domain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time From Randomization to Respiratory Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dental Caries reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inspiratory and expiratory muscle force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Markers of ovarian reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Peripheral Blood Lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peripheral Hydrogen Ions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peripheral Blood pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Selective voluntary motor control of upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Characteristic Pain Intensity (CPI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Response to sorafenib therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Agreement between Transferrin Saturation Coefficient (TSC) and ferritinemia dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total score on the ADHD Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance Walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yale Global Tic Severity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of positive cultures for M. hominis, U. urealyticum and C. trachomatis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in urine protein excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean Percentage of Work Time Missed (Absenteeism)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean Percentage of Impairment While Working Due to RA (Presenteeism)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean Percentage of Overall Work Productivity Impairment (OWPI) Due to RA
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: colorectal cancer rate
Endpoint domain: Mortality/survival
Primary endpoint: Clinical cure at the Test of Cure visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mycological eradication at the Test of Cure visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Comparison of propofol administration methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of NT-proBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Survival at Day 60
Endpoint domain: Mortality/survival
Primary endpoint: Residual rate of AVMs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Acute Kidney Injury (AKI)-Free Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants Who Receive 3 or More Ultrasound Volume Assessments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Day 28 cure rate
Endpoint domain: Mortality/survival
Primary endpoint: Day 7 cure rate
Endpoint domain: Mortality/survival
Primary endpoint: Plasmatic concentrations of biomarkers specific to pulmonary aggression of ARDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Outcomes of tetanus patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of hypervascular pancreatic neoplasms detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Vaginal Colony Counts (Anaerobic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Vaginal Colony Counts (Aerobic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Laboratory anomalies
Endpoint domain: Adverse events/effects
Primary endpoint: Mean K-BILD score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes from baseline in 12 lead ECG parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in immunoglobulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 24-hour urine creatinine clearance (Single Ascending Dose Period)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Local tolerability of injected drug product
Endpoint domain: Adverse events/effects
Primary endpoint: 1-year rate of Locoregional Disease Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Duration of time on mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: DIAGNOdent Readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glomerular filtration rate (mL/min/1.73m2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Concentration of creatinine (mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Concentration of liver transaminases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with complete cytogenetic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants with major molecular response (MMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of symptomatic, recurrent VTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Overall day 42 cure rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in self-reported severity of pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rifapentine pharmacokinetic parameters (AUC0-24 and peak concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under curve of FEV1 from 0 to 120 minutes (AUC0-120min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Bone Mineral Density (BMD) of the Lumbar Spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Subjects Who Develop Endoscopically-diagnosed Upper Gastrointestinal Ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: response rate (Phase Ib)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety and tolerability of rituximab
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline of CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Histological changes of antibody mediated rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optic nerve and choroidal blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum Observed Concentration in Plasma of CC-115
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of PIIRs
Endpoint domain: Adverse events/effects
Primary endpoint: Time From Cervical Ripening to Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with diameter stenosis >50% of saphenous vein graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Maximal HO-1 mRNA expression in PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in distress score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in perceived stress scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in serum cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in serum epinephrine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Metabolic Syndrome (MetS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24-hour Voiding Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: First pass success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in luminal patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants who die during observation
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants undergoing lung Transplantation during observation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Device failures
Endpoint domain: Adverse events/effects
Primary endpoint: RSV viral load measured in nasal secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants reporting one or more treatment-emergent adverse event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants who discontinue due to an adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Free From Progression at 3 Years
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Reported AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Safety-Related Study Drug Discontinuations
Endpoint domain: Adverse events/effects